Dr Boreham's Crucible: Regeneus is now riding the stem cell rollercoaster upwards

Business and life sciences writer Tim Boreham recently featured Regeneus in his regular biotech stocks column, Dr Boreham’s Crucible.

The column, published on Stockhead, reported that Regeneus' deal with Kyocera was important as it provided a clear commercialisation pathway for the lead stem cell platform technology Progenza.

Read the full article via Stockhead here.